WINNING ABSTRACT: Sleep-disordered breathing (SDB) is often associated with impaired glucose metabolism. The study aimed at assessing immediate effect of CPAP on glucose excursions in type 2 diabetic patients with SDB measured with 72-hour continuous glucose monitoring system (CGMS , HbA1c 7,3¡1,4%) underwent 2 overnight polysomnographic examinations including diagnostic night and CPAP night. CGMS was applied on both occasions. Statistical analyses included paired Student's t-test.
improvement of saturation. Frequent episodes of sleep apnoea/hypopnoea and severe oxygen desaturation were followed by significant rise in blood glucose of up to 12,3 mmol?l -1 . Duration of post-hypoxic hyperglycemia was 50¡10,79 min and its climax tended to be appeared up to 45min post-hypoxia. Nocturnal hyperglycemia strongly correlated with severe oxygen desaturation. Nocturnal glucose values were significantly higher during diagnostic night than during CPAP night (8,19¡0,99 mmol?l -1 versus 6,77¡1,47 mmol?l -1 ; p,0,0001). CGMS also showed improved preprandial and 1,5-hour postprandial glucose levels for breakfast after CPAP night. The improvement in overall glucose levels was much greater in patients with BMI,30 kg?m -2 than in more obese patients.
The results suggest that nocturnal hyperglycemia is closely related to desaturation and CPAP treatment may have an immediate decreasing effect on blood glucose in type 2 diabetic patients with SDB. Besides my clinical research work, I also participate in the practical teaching of undergraduate students of general medicine, who are in the second year of their 6 yr-long course.
Maria Pallayova
There are two semesters of human physiology, which is an important science studying the way that cells, tissues and organs work in people. the sleep medicine research area of our department. I focus my research specifically on endocrine and metabolic aspects of sleep apnoea. Similar clustering of cardiovascular disease risk factors, one of which involves insulin resistance characteristic in type 2 diabetes, is also typical for patients with SDB. Sleep apnoea goes with diabetes and diabetes goes with sleep apnoea, and together these present a very dangerous combination. Diabetes itself has been described as a silent killer because of its late complications affecting the eyes, kidneys, nerves and large and small blood vessels, being strongly related to hyperglycaemias. The goal of effective diabetes management is to control blood glucose levels by keeping them within a target range, which is the best way to minimise the risk of these complications. Untreated sleep apnoea with recurrent episodes of airflow obstruction and hypoxaemia may adversely influence metabolic and glycaemic control, and contributes to the development of late diabetes complications. Several studies have suggested that OSAHS is pathophysiologically related to impaired glucose homeostasis and that CPAP is an important therapy with the potential to also improve insulin responsiveness. However, current data regarding the effects of CPAP on glycaemia are conflicting and often lacking in proper investigational methods. We hypothesise that CPAP may improve glycaemic control in sleep apnoea patients who also suffer from type 2 diabetes. Our aim was to assess an immediate CPAP effect on glycaemia in patients with severe SDB and concomitant type 2 diabetes using the CGMS in parallel with overnight PSG, which is the subject of my abstract.
MY WINNING ABSTRACT AS PART OF MY RESEARCH

THE IMPACT OF MY WORK ON CLINICAL OR RESEARCH PRACTICE
Obstructive sleep apnoea is not only an obstruction, it is a cardiovascular and metabolic nightmare. SDB is widely unrecognised in the type 2 diabetic population and this condition is linked to increased use of medical resources. The diagnosis and treatment of SDB is a growing and vitally important field. CGMS in parallel with overnight PSG has a potential to also detect abnormal nocturnal glucose patterns related to OSAHS not previously identified. Our results indicate that nocturnal increment in blood glucose expressed as the hyperglycaemic area under the glucose concentration curve during 8-h period of night was significantly higher for diagnostic nights (before CPAP) compared with CPAP nights, and was strongly negatively correlated with severe oxygen desaturation. Mean nocturnal glucose values were significantly higher during diagnostic nights as compared with CPAP nights. CGMS has also shown improved pre-and postprandial glucose levels for breakfast after the CPAP night. We suggest that improved glucose control under CPAP may reflect decreased sympathetic activity and improved insulin sensitivity, which is determined not only by obesity but by sleep apnoea. Our results indicate that CPAP is a highly effective tool for restoring normal breathing in OSAHS and has the potential to improve glycaemic control in patients with concomitant type 2 diabetes. Diagnosis and treatment of sleep apnoea can contribute to an improved quality of life and may decrease apnoea-and also diabetes-related morbidity and mortality. Detailed data from CGMS and parallel PSG can assist in designing an individualised diabetes and sleep apnoea treatment programme and may facilitate comprehensive management recommendations.
